Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 22.59
- Piotroski Score 3.00
- Grade Outperform
- Symbol (ICVX)
- Company Icosavax, Inc.
- Price $15.31
- Changes Percentage (-0.91%)
- Change -$0.14
- Day Low $15.28
- Day High $15.44
- Year High $16.11
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $27.00
- High Stock Price Target $27.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.20
- Trailing P/E Ratio -6.9590909090909
- Forward P/E Ratio -6.9590909090909
- P/E Growth -6.9590909090909
- Net Income $-88,458,000
